Trevi Therapeutics Pre-Tax Income 2018-2025 | TRVI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trevi Therapeutics pre-tax income from 2018 to 2025. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

Trevi Therapeutics Pre-Tax Income 2018-2025 | TRVI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Trevi Therapeutics pre-tax income from 2018 to 2025. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.6B
Amgen (AMGN)	$164.4B
Gilead Sciences (GILD)	$137B
Vertex Pharmaceuticals (VRTX)	$120.7B
Bristol Myers Squibb (BMY)	$97.7B
CSL (CSLLY)	$84.2B
GSK (GSK)	$75.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$42.4B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$20.3B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$16.2B
Genmab (GMAB)	$14B
Genmab (GNMSF)	$13.8B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.1B
Exact Sciences (EXAS)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.8B